Lista de obras - Ole Lederballe-Pedersen - Dominio Público Uruguay

Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study

scientific article published on 01 December 2003

Ambulatory blood pressure monitoring after 1 year on valsartan or amlodipine-based treatment: a VALUE substudy

article by Ole Lederballe Pedersen et al published March 2007 in Journal of Hypertension

Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy

scientific article published on 01 February 2007

Body build and risk of cardiovascular events in hypertension and left ventricular hypertrophy: the LIFE (Losartan Intervention For Endpoint reduction in hypertension) study

artículo científico publicado en 2005

Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

artículo científico publicado en 2002

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

artículo científico publicado en 2002

Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy

artículo científico publicado en 2004

Effects of losartan compared with atenolol on lipids in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension study

artículo científico publicado en 2009

Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy

artículo científico publicado en 2002

Effects of losartan or atenolol in hypertensive patients without clinically evident vascular disease: a substudy of the LIFE randomized trial

artículo científico publicado en 2003

Independent clinical intervention research--or evidence-biased medicine?

artículo científico publicado en 2005

Losartan benefits over atenolol in non-smoking hypertensive patients with left ventricular hypertrophy: the LIFE study

artículo científico publicado en 2004

Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: an analysis of findings from the VALUE trial

scientific article published on 01 November 2006

Predictors of cardiovascular events in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention for Endpoint reduction in hypertension study

artículo científico publicado en 2009

Prognostic importance of hemoglobin in hypertensive patients with electrocardiographic left ventricular hypertrophy: the Losartan Intervention For End point reduction in hypertension (LIFE) study

artículo científico publicado en 2008

Pulse pressure and effects of losartan or atenolol in patients with hypertension and left ventricular hypertrophy

artículo científico publicado en 2005

Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study

artículo científico publicado en 2005

Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study

artículo científico publicado en 2002

Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study

artículo científico publicado en 2004

Targeting the renin-angiotensin system for the reduction of cardiovascular outcomes in hypertension: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers

artículo científico publicado en 2005

The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with diabetes mellitus in the LIFE-study

artículo científico publicado en 2003

The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension and ECG-verified left ventricular hypertrophy in the LIFE-study

artículo científico publicado en 2003

The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension taking aspirin: the Losartan Intervention for Endpoint Reduction in hypertension (LIFE) study

artículo científico publicado en 2005

The effects of losartan compared to atenolol on stroke in patients with isolated systolic hypertension and left ventricular hypertrophy. The LIFE study

artículo científico publicado en 2005

The impact of serum uric acid on cardiovascular outcomes in the LIFE study

artículo científico publicado en 2004

[Dual blockade of the renin-angiotensin system--is it of clinical significance?]

artículo científico publicado en 2004

[Home blood pressure measurement in general practice]

scientific article published on 01 March 2006

[Pharmacological hypertension therapy]

artículo científico publicado en 2009

Lista de obras de Ole Lederballe-Pedersen

Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study

Ambulatory blood pressure monitoring after 1 year on valsartan or amlodipine-based treatment: a VALUE substudy

Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy

Body build and risk of cardiovascular events in hypertension and left ventricular hypertrophy: the LIFE (Losartan Intervention For Endpoint reduction in hypertension) study

Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy

Effects of losartan compared with atenolol on lipids in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension study

Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy

Effects of losartan or atenolol in hypertensive patients without clinically evident vascular disease: a substudy of the LIFE randomized trial

Independent clinical intervention research--or evidence-biased medicine?

Losartan benefits over atenolol in non-smoking hypertensive patients with left ventricular hypertrophy: the LIFE study

Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: an analysis of findings from the VALUE trial

Predictors of cardiovascular events in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention for Endpoint reduction in hypertension study

Prognostic importance of hemoglobin in hypertensive patients with electrocardiographic left ventricular hypertrophy: the Losartan Intervention For End point reduction in hypertension (LIFE) study

Pulse pressure and effects of losartan or atenolol in patients with hypertension and left ventricular hypertrophy

Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study

Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study

Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study

Targeting the renin-angiotensin system for the reduction of cardiovascular outcomes in hypertension: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers

The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with diabetes mellitus in the LIFE-study

The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension and ECG-verified left ventricular hypertrophy in the LIFE-study

The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension taking aspirin: the Losartan Intervention for Endpoint Reduction in hypertension (LIFE) study

The effects of losartan compared to atenolol on stroke in patients with isolated systolic hypertension and left ventricular hypertrophy. The LIFE study

The impact of serum uric acid on cardiovascular outcomes in the LIFE study

[Dual blockade of the renin-angiotensin system--is it of clinical significance?]

[Home blood pressure measurement in general practice]

[Pharmacological hypertension therapy]